ClinicalTrials.gg
RecruitingNCT05007834METAB-OVUpdated Dec 26, 2025

Metabolism, Circadian Rhythms and Ovarian Function

An observational study in Chemotherapy-Induced Amenorrhea, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to female participants aged 25 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
25 Years to 35 Years
Sex
Female
01

Study summary

Chemotherapy for cancer, due to its gonadotoxicity, can lead to impaired female fertility, resulting in the occurrence of transient or prolonged chemo-induced amenorrhea (CIA). According to recent data from the National Cancer Institute, 11.9% of women under the age of 40 diagnosed with cancer have been offered a fertility evaluation within five years of diagnosis. Predicting the risk and especially the duration of the CIA remains difficult. Known factors predicting a rapid return of menstruation are a young age at diagnosis, a low gonadotoxic treatment (absence of alkylating agents) and a high pre-chemotherapy blood level of AMH reflecting a large pool of growing follicles. A body mass index (BMI) ≥ 25 kg / m² could also be a positive predictor, but this remains debated.

The objective of this project is to assess the impact of metabolism and energy reserves, physical activity and the chronotype on the recovery of ovarian function in patients with breast cancer who have developed CIA

02

Conditions studied

  • Chemotherapy-Induced Amenorrhea

Browse trials for

Keywords

  • Ovarian recovery
  • Metabolism
  • Muscular mass
  • Adipose tissue
  • Chronotype
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 50 is below the median of 85 across 26 observational studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with a chemotherapy-induced (CIA) amenorrhea who asked for post-cancer fertility follow-up at the University Hospital of Lille, France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with a chemotherapy-induced (CIA) amenorrhea who asked for post-cancer fertility follow-up at the University Hospital of Lille, France.
  • Women between 25 to 35 years age at inclusion
  • Chemotherapy protocol: FEC 100 (3 cycles) + docetaxel (3 cycles

Exclusion criteria

Exclusion Criteria:

  • Women without CIA
  • Women who refuse to participate in the study
  • Women older than 35 years at inclusion
  • Women who received another chemotherapy protocol
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Concentration of IL-6 levels at the end of chemotherapy

    Study the association between the IL-6 blood levels (in pg/ml) at the end of chemotherapy and the menstrual period return state ( before or after 6 months)

    Time frame: 1 year

Secondary outcomes

  1. Correlation between blood metabolic markers (Leptin, Insulin, Ghrelin) and menstrual period return state

    Leptin concentration in ng/ml; insulin concentration in mUI/L; ghrelin concentrations in pg/ml

    Time frame: 1 year

  2. Correlation between physical activity score at the end of chemotherapy and menstrual period return state

    Physical activity score expressed in arbitrary units

    Time frame: 1 year

  3. Correlation between chronotype score at the end of chemotherapy and menstrual period return state

    chronotype score expressed in arbitrary units

    Time frame: 1 year

  4. Correlation between the BMI at the end of chemotherapy and menstrual period return state

    weight and height will be combined to report BMI in kg/m2

    Time frame: 1 year

  5. Correlation between Blood metabolic markers (Leptin, Insulin, Ghrelin) assessed at 3 months and menstrual period return state

    Leptin concentration in ng/ml, Insulin concentration in mUI/L, Ghrelin concentration in pg/ml

    Time frame: 9 months

  6. Correlation between the Physical activity Score at 3 months and the menstrual period return state (between 3 to 12 months)

    Physical activity score expressed in arbitrary units

    Time frame: 9 months

  7. Correlation between the BMI assessed at 3 months and the menstrual period return state (between 3 to 12 months)

    weight and height assessed at 3 months will be combined to report BMI in kg/m2

    Time frame: 9 months

  8. Evolution of the blood concentration of insulin over the follow-up period (12 months)

    insulin concentrations expressed in mUI/L

    Time frame: 1 year

  9. Correlation between the Chronotype Score at 3 months and the menstrual period return state (between 3 to 12 months)

    chronotype score expressed in arbitrary units

    Time frame: 9 months

  10. Evolution of the blood concentration of Leptin over the follow-up period (12 months)

    leptin concentrations expressed in ng/ml

    Time frame: 1 year

  11. Evolution of the blood concentration of Ghrelin over the follow-up period (12 months)

    ghrelin concentrations expressed in pg/ml

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Jun 2026, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2021
First posted
Aug 16, 2021
StartActual
Feb 24, 2022
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05007834
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Feb 24, 2022
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Pascal PIGNY, MD,PhD
Contact
pascal.pigny@chru-lille.fr
0320445962 ext. +33
Pascal PIGNY, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion